Claire Crafter

Publications by Year

Research Areas

Computational Drug Discovery Methods, PI3K/AKT/mTOR signaling in cancer, Prostate Cancer Treatment and Research, Biosimilars and Bioanalytical Methods, Cancer, Lipids, and Metabolism

Most-Cited Works

• → Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background(2012)457 cited
• → AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis(2007)356 cited
• → Validating Aurora B as an anti-cancer drug target(2006)283 cited
• → Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase(2007)273 cited
• → Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases(2013)213 cited
• → Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer(2018)189 cited
• → Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo(2013)150 cited
• → Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens(2020)110 cited
• → Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models(2014)107 cited
• → Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel(2014)99 cited